Skip to main content icon/video/no-internet

Tay-Sachs disease (TSD), or GM2 gangliosidosis, is a fatal genetic lipid storage disorder where harmful quantities of the fatty substance ganglioside GM2 build up in tissues and nerve cells in the brain. This is from insufficient activity of the enzyme beta-hexosaminidase A which catalyzes (speeds up) the breakdown of acidic fatty materials or gangliosides. This is especially important in the growing infant as gangliosides are produced and broken down rapidly as the brain develops. Globally, Tay-Sachs disease is underdiagnosed and undertreated. In the developing world, most healthcare facilities do not have the ability to properly diagnose this genetic disorder and lack the resource to ease suffering as TSD cannot be cured.

Infants with TSD seem to develop normally for the first few months of life. However, as development continues, nerve cells grow and wrap in the fatty material that enables transmission. In TSD, an unhealthy accumulation occurs and stops this growth process. Blindness, deafness, and other simple actions such as swallowing become impossible. The British ophthalmologist Dr. Warren Tay first observed a red spot on the retina in the late 19th century and American neurologist Dr. Bernard Sachs was able to describe the cellular changes that occur in TSD. He was also able to identify an increase in TSD for those of eastern European Jewish (Ashkenazi) decent.

Genetic Disorder

More specifically, TSD is an autosomal recessive (not sex-linked and both parents must be carriers to have a child with TSD) disease that occurs when harmful quantities of the fatty acid derivative ganglioside accumulate in nerve cells in the brain. Ganglioside GM2 in Tay-Sachs disease is especially common in the nervous tissue of the brain. Mutations on chromosome 15 and specific to the hexosaminidase A (alpha polypeptide) or HEXA gene are what cause TSD.

Many of these mutations have been discovered and more than 90 mutations have been identified in the HEXA gene. New mutations are still being reported and research is still under way. These mutations include base pair insertions and deletions, splice site mutations, point mutations, and other more complex patterns. Each of these mutations alter the protein product and inhibit the function of the enzyme in some manner causing TSD.

Some populations have higher mutation frequencies than others. For example, French Canadians of southeastern Quebec and Cajuns from southern Louisiana have mutation frequencies similar to those mentioned for Ashkenazi Jews of eastern Europe. TSD can occur from inheritance of two unrelated mutations involving the HEXA gene with one being from each parent.

Types

The juvenile-onset form presents with loss of coordination and dementia. Death ensues by age 10 to 15 years. The adult-onset form is characterized by clumsiness in childhood with progressive motor weakness in adolescence and multiple and neurological disorders with balance, speech, and overall movement. Intelligence declines slowly, and psychosis can occur.

Diagnosis

A simple blood test looking for hexosaminidase A activity can diagnose TSD. Even though this disease is autosomal recessive and both parents have to carry the gene, it is only a 25 percent chance that the child will be born with TSD. Furthermore, prenatal monitoring in the fetus by chorionic villus sampling or amniocentesis is an option. Screening for Tay-Sachs disease carriers is recommended in the Ashkenazi Jewish population.

...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles

Sage Recommends

We found other relevant content for you on other Sage platforms.

Loading